By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Qualcomm And Boehringer Ingelheim Collaborate To Add New Digital Technology To RESPIMAT Inhaler 8/30/2016 8:51:07 AM
Boehringer Ingelheim And Duke Clinical Research Institute Expand Collaboration To Create Largest Patient Registry For Idiopathic Pulmonary Fibrosis (IPF) 8/25/2016 9:36:54 AM
Boehringer Ingelheim Launches RE-VECTO Global Program To Capture Data On Praxbind (Idarucizumab) Usage In Clinical Practice 8/15/2016 9:25:29 AM
CANBridge Life Sciences Signs Agreement With Boehringer Ingelheim To Manufacture Inhibitory Antibody, CAN-017, For Esophageal Squamous Cell Cancer 8/11/2016 11:44:25 AM
Boehringer Ingelheim Release: First Study Initiated To Evaluate The Effect Of Ofev Treatment On Biomarkers That May Predict IPF Progression 7/27/2016 6:17:33 AM
Boehringer Ingelheim Halts Two Phase III Trials for Lung Cancer Drug Gilotrif 7/26/2016 7:23:42 AM
The European Stroke Organization And Boehringer Ingelheim Launch The "Angels Initiative", A Unique Healthcare Initiative To Improve Acute Stroke Care Across Europe 7/20/2016 11:26:58 AM
Boehringer Ingelheim And University of Dundee Collaborate To Develop New Class Of Medicines 7/14/2016 10:25:36 AM
Boehringer Ingelheim And Eli Lilly (LLY) Announce Clinical Trial Collaboration In Metastatic Breast Cancer 7/13/2016 10:29:28 AM
Boehringer Ingelheim Release: INMARK Now Enrolling: First Study To Evaluate The Effect Of OFEV (Nintedanib) On Biomarkers Reflecting The Underlying Fibrotic Process In IPF Patients 6/30/2016 9:03:29 AM